The stock market is set for a positive start to the week with Robinhood, Sandisk, AMD and Moderna already in buy areas.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

The biotech is entering a new era.

After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.

Personalized cancer vaccines are attracting growing attention as advances in mRNA technology open up new possibilities across oncology.

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Moderna co-founder Bob Langer and AI pioneer Yann LeCun join Cellular Intelligence's board as the startup builds a foundation ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its ...

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of skin cancer—in a late-stage trial involving more than 1,100 patients, and ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock ...